New England Securities’s PDL BioPharma, Inc. PDLI Stock Holding History

New England Securities’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$26K	Buy	3,340 +5	+0.1%	+$40	0.01%	799
2014 Q3	$25K	Buy	3,335 +250	+8%	+$2.32K	0.01%	843
2014 Q2	$30K	Buy	3,085 +2,862	+1,283%	+$25.5K	0.01%	771
2014 Q1	$2K	Hold	223	–	–	﹤0.01%	1586
2013 Q4	$2K	Buy	+223	New	+$1.88K	﹤0.01%	1521

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

New England Securities's PDLI Position: Q4 2014 in Review

New England Securities increased its PDL BioPharma, Inc. (PDLI) stake by 0.15% in Q4 2014, buying an estimated $40 and bringing the position to 3,340 shares worth $26K. The position accounts for 0.01% of the portfolio, ranked #799.

New England Securities first reported a position in PDLI in Q4 2013 and has held it in 5 quarters since. The position peaked at $30K in Q2 2014. 223 funds tracked by Wall St. Rank hold PDLI as of Q4 2014.

New England Securities held 3,340 shares of PDL BioPharma, Inc. worth $26K as of Q4 2014.
New England Securities bought 5 PDL BioPharma, Inc. shares in Q4 2014, an estimated $40.
PDL BioPharma, Inc. made up 0.01% of New England Securities's portfolio in Q4 2014, its #799 holding.
New England Securities first reported a position in PDL BioPharma, Inc. in Q4 2013 and has held it in 5 quarters since.
New England Securities's PDL BioPharma, Inc. position peaked at $30K in Q2 2014.
223 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.